BioCryst Pharmaceuticals, Inc. (BCRX) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
BCRX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a price-to-earnings ratio of 7.4x, with a stock price of $8.90 and trailing twelve-month earnings per share of $-1.89.
The current P/E is 13% above its 5-year average of 6.5x. Over the past five years, BCRX's P/E has ranged from a low of 6.5x to a high of 6.5x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, BCRX trades at a 67% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, BCRX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BCRX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | - | +68% | |
| $5B | 8.3Lowest | - | +264%Best | |
| $49B | 40.1 | - | +54% | |
| $8B | 25.5 | 1.11Best | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
BCRX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $7.80 | $1.20 | 6.5x | +0% |
Average P/E for displayed period: 6.5x
See BCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
Is BCRX stock overvalued or undervalued?
BCRX trades at 7.4x P/E, near its 5-year average of 6.5x. The 100th percentile ranking places valuation within normal historical bounds.
How does BCRX's valuation compare to peers?
BioCryst Pharmaceuticals, Inc. P/E of 7.4x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is BCRX's PEG ratio?
BCRX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.